Skip to main content
SpringerLink
Log in

Drug therapy of osteoporosis

  • Chapter
Balloon Kyphoplasty

Abstract

Drug therapy of osteoporosis is fundamentally changing. Treatments that are available today can halve the risk of a vertebral fracture within months. These drugs are effective at the cellular level, either by inhibiting the resorption of bone via direct or indirect effects on osteoclasts, or, as in the case of teriparatide, by the almost exclusive induction of osteoblasts. The latest development is stable strontium, the salt of ranelic acid. Strontium ranelate is the first drug that simultaneously increases osteogenesis and decreases bone resorption. Recombinant monoclonal antibodies that influence the regulation of osteoclasts at the cytokine level are also currently being developed. Thus in future, in addition to the two present categories of osteotrophic substances (absorption-inhibiting and bone-increasing compounds), there will be two new categories: dual-acting bone agents (DABAs) and cytokines or biologicals.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aloia JF, Vaswani A, Yeh JK, Ellis K, Yasumura S, Cohn S (1988) Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med 84: 401–408

    Article  PubMed  CAS  Google Scholar 

  • American Association of Clinical Endocrinologists (2001) Medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocrine Pract 4(7): 294–312

    Google Scholar 

  • Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD (2002) Raloxifene and cardiovascular events in osteoporotic postmenopausal women. JAMA 287(7): 847–857

    Article  PubMed  CAS  Google Scholar 

  • Bekker P, Holloway D, Rasmussen A, Murphy R, Martin S, Leese P, Holmes G, Dunstan C, DePaoli A (2004) A single-dose-controled study af AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19: 1059–1066

    Article  PubMed  CAS  Google Scholar 

  • Berning B, Kuijk CV, Kuiper JW, Bennink HJ, Kicovic PM, Fauser BC (1996) Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study. Bone 19(4): 395–399

    Article  PubMed  CAS  Google Scholar 

  • Bjarnason NH, Bjarnason K, Hassager C, Christiansen C (1997) The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women. Bone 20(2): 151–155

    Article  PubMed  CAS  Google Scholar 

  • Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, et al (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349: 1207–1215

    Article  PubMed  CAS  Google Scholar 

  • Black DM, Steinbuch M, Palermo L, Dargent-Molina P, Lindsay R, Hoseyni MS, Johnell O (2001) An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 12: 519–528

    Article  PubMed  CAS  Google Scholar 

  • Boivin G, Deloffre P, Perrat B, Panczer G, Boudeulle M, Mauras Y, Allain P, Tsouderos Y, Meunier PJ (1996) Strontium distribution and interactions with bone mineral in monkey Iliac bone after Strontium Salt (S12911) Administration. J Bone Miner Res 11(9): 1302–1311

    PubMed  CAS  Google Scholar 

  • Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA (2004) Ten years experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189–1199

    Article  PubMed  CAS  Google Scholar 

  • Brown JP, Kendler DL, McCLung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R (2002) The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71: 103–111

    Article  PubMed  CAS  Google Scholar 

  • Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, Le Boff M; Women’s Health Initiative Investigators, et al (2003) Women’s Health Initiative Investigators: effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 290: 1729–1738

    Article  PubMed  CAS  Google Scholar 

  • Chapuy MC, Arlot ME, Delmas PD, Meunier PJ (1994) Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 308: 1081–1082

    PubMed  CAS  Google Scholar 

  • Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ (1992) Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327: 1637–1642

    PubMed  CAS  Google Scholar 

  • Chesnut CH III, Silverman S, Andriano K, et al (2000) (PROOF Study Group). A randomized trial of nasal spry salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 109: 267–276

    Article  PubMed  CAS  Google Scholar 

  • Chestnut CH, Skag A, Christiansen C, et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19: 1241–1249

    Article  CAS  Google Scholar 

  • Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, et al (2002) Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23: 508–516

    Article  PubMed  CAS  Google Scholar 

  • Cumming RG, Nevitt MC (1997) Calcium for prevention of osteoporotic fractures in postmenopausal women. J Bone Miner Res 12: 1321–1329

    Article  PubMed  CAS  Google Scholar 

  • Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112: 281–289

    Article  PubMed  CAS  Google Scholar 

  • Cummings SR (2001) The paradox of small changes in bone density and reductions in risk of fracture with raloxifene. Ann N Y Acad Sci 949: 198–201

    Article  PubMed  CAS  Google Scholar 

  • Dawson-Hughes B, Dallai GE, Krall EA, Sadowski L, Sahyoun N, Tannenbaum SA (1990) A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 323: 878–883

    PubMed  CAS  Google Scholar 

  • Dawson-Hughes B, Harris SS, Krall EA, Dalla GE (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. NEJM 337: 670–676

    Article  PubMed  CAS  Google Scholar 

  • Dimai HP, Pietschmann P, Resch H, Klaushofer K (2002) Leitfaden zur medikamentösen Therapie der postmenopausalen Osteoporose. Für die EBM-Arbeitsgruppe der Österr. Ges. zur Erforschung des Knochens und Mineralstoffwechsels (AuSBMR). Wien Med Wochenschr 152(23–24): 596

    Article  PubMed  CAS  Google Scholar 

  • Dobnig H, Turner RT (1995) Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136: 3632–3638

    Article  PubMed  CAS  Google Scholar 

  • Dobnig H, Turner RT (1997) The effects of programmed administration of human parathyroid hormone fragment (1–34) on bone histomorphometry and serum chemistry in rats. Endocrinology 138: 4607–4612

    Article  PubMed  CAS  Google Scholar 

  • Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glueer CC, Krueger K, Cohen FJ, Eckert S, Ensrud K, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282: 637–645

    Article  PubMed  CAS  Google Scholar 

  • Farley JR, Tarbaux N, Baylink DJ (1983) Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone-forming cells. Science 222: 330–332

    Article  PubMed  CAS  Google Scholar 

  • Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM, et al (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349: 1216–1226

    Article  PubMed  CAS  Google Scholar 

  • Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM (1994) Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 331(24): 1618–1623

    Article  PubMed  CAS  Google Scholar 

  • Fratzl P, Roschger P, Eschberger J, Abendroth B, Klaushofer K (1994) Abnormal bone mineralization after fluoride treatment in osteoporosis: a small-angle x-ray scattering study. J Bone Miner Res 9(10): 1541–1549

    PubMed  CAS  Google Scholar 

  • Frost HM (2001) Should future risk-of-fracture analyses include another major risk factor? The case for falls. J Clin Densitom 4(4): 381–383

    Article  PubMed  CAS  Google Scholar 

  • Gallagher JC, Baylink DJ, Freeman R, McClung M (2001) Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 86(10): 4717–4726

    Article  PubMed  CAS  Google Scholar 

  • Gallagher JC, Goldgar D (1990) Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. Ann Int Med 113: 649–655

    PubMed  CAS  Google Scholar 

  • Haguenauer D, Welch V, Shea B, Tugwell P, Adachi JD, Wells G (2000) Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta analysis. Osteoporos Int 11: 727–738

    Article  PubMed  CAS  Google Scholar 

  • Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD (2002) Changes in bone density and turnover explain the reduction in incidence of non-vertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87(4): 1586–1592

    Article  PubMed  CAS  Google Scholar 

  • Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D (1999) Larger increases in bone mineral density during alendronate are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 42(6): 1246–1254

    Article  PubMed  CAS  Google Scholar 

  • Hofbauer LC, Kuhne CA, Viereck V (2004) The OPG/ RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 4(3): 268–275

    PubMed  CAS  Google Scholar 

  • Hsu H, Lacey DL, Dunstan CR, et al (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96: 3540–3545

    Article  PubMed  CAS  Google Scholar 

  • Kanis JA, WHO Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 4: 368–381

    Article  PubMed  CAS  Google Scholar 

  • Khan SA, de Geus C, Holroyd B, Russel AS (2001) Osteoporosis follow-up after wrist fractures following minor trauma. Arch Intern Med 161: 1309–1312

    Article  PubMed  CAS  Google Scholar 

  • Klaushofer K, Peterlik M (1996) Pathophysiology of osteoporosis. In: Bröll H, Dambacher MA (eds) Osteoporosis: a guide to diagnosis and treatment. Karger, Basel

    Google Scholar 

  • Kleerekoper M (1996) Fluoride and the skeleton. Crit Rev Clin Lab Sci 33(2): 139–161

    Article  PubMed  CAS  Google Scholar 

  • Kloosterboer HJ (2001) Tibolone: a steroid with a tissuespecific mode of action. Steroid Biochem Mol Biol 76: 231–238

    Article  CAS  Google Scholar 

  • Klotzbuecher CM, Ross PD, Landsman PB, Abbot TA III, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15: 721–739

    Article  PubMed  CAS  Google Scholar 

  • Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos SA, Van G, Khoo W, Wakeham A, Dunstan CR, LAcey DL, Mak TW, Boyle WJ, Penninger JM (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis. Nature 397: 315–323

    Article  PubMed  CAS  Google Scholar 

  • Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP, et al (2000) Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85: 3069–3076

    Article  PubMed  CAS  Google Scholar 

  • Lacey DL, et al (1998) Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoklast differentiation and activation. Cell 93: 165–176

    Article  PubMed  CAS  Google Scholar 

  • Looker AC, Bauer DC, Chesnut III CH, Gundberg CM, Hochberg MC, Klee G, Kleerekoper M, Watts NB, Bell NH (2000) Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int 11: 467–480

    Article  PubMed  CAS  Google Scholar 

  • Lyritis GP, Loannidis GV, Karachalios T, Roidis N, Kataxaki E, Papaiannou N, Kaloudis J, Galanos A (1999) Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study. Clin J Pain 15(4): 284–289

    Article  PubMed  CAS  Google Scholar 

  • Mackerras D, Lumley T (1997) First and second-year effects in trials of calcium supplementation on the loss of bone density in postmenopausal women. Bone 21(6): 527–533

    Article  PubMed  CAS  Google Scholar 

  • Marcus R, Holloway L, Wells B, Greendale G, James MK, Wasilauskas C, Keleghan J (1999) The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Bone Miner Res 14: 1583–1595

    Article  PubMed  CAS  Google Scholar 

  • Marcus R, Wong Mayme, Heath H, Stock JL (2002) Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 23: 16–37

    Article  PubMed  CAS  Google Scholar 

  • Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15: 613–620

    Article  PubMed  CAS  Google Scholar 

  • Meunier PJ, Roux C, Seemann E, Ortalani S, et al (2004) The effects of strontium ranelate on the risk of vertebral fracture on women with postmenopausal osteoporosis. N Engl J Med 350: 459–468

    Article  PubMed  CAS  Google Scholar 

  • Meunier PJ, Slosman DO, Delmas PD, et al (2002) Strontium ranelate: Dose dependent effects in established postmenopausal vertebral osteoporosis — A 2 year randomized placebo controlled trial. J Clin Endocrinal Metab 87: 2060–2066

    Article  CAS  Google Scholar 

  • Miller PD, Barran DT, Bilezikian JT (1999) Practical clinical applications of biochemical markers of bone turnover: consensus of an expert panel. J Clin Densitom 2: 323–342

    Article  PubMed  CAS  Google Scholar 

  • Mitlak BH, Cohen FJ (1999) Selective estrogen receptor modulators: a look ahead. Drugs 57: 653–663

    Article  PubMed  CAS  Google Scholar 

  • Mundy GR, Guise TA (1999) Hormonal control of calcium homeostasis. Clin Chem 45(8): 1347–1352

    PubMed  CAS  Google Scholar 

  • Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19): 1434–1441

    Article  PubMed  CAS  Google Scholar 

  • Orwoll E, Ettinger M, Weiss, et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343: 604–610

    Article  PubMed  CAS  Google Scholar 

  • Pak CYC, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR (1995) Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Ann Int Med 123: 401–408

    PubMed  CAS  Google Scholar 

  • Parfitt AM (1979) Quantum concept of bone remodelling and turnover: implications for the pathogenesis of osteoporosis. Calcif Tissue Int 28: 1–5

    Article  PubMed  CAS  Google Scholar 

  • Recker RR, Hinders S, Davis KM, Heaney RP, Stegman MR (1996) Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res 11: 1961–1966

    PubMed  CAS  Google Scholar 

  • Recker RR, Kendler DL, Adami S, Hughes C, Dumont E, Schimmer RC, Cooper C (2004a) Monthly oral ibandronate significantly reduces bone resorption in postmenopausal osteoporosis: 1-year results from MOBILE. Poster SA406, presented at: 26th Annual Meeting of the American Society for Bone Mineral Research, October 1–5, Seattle, WA

    Google Scholar 

  • Recker RR, Reid DM, Sambrook, P, Hughes C, Ward P, Bonvoisin B, Adami S (2004b) Intermittent intravenous ibandronate injection regimens provide at least equivalent efficacy to daily Oral Ibandronate: 1-year results from DIVA. Arthritis Rheum 50 [Suppl]: S 513

    Google Scholar 

  • Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11: 83–91

    Article  PubMed  CAS  Google Scholar 

  • Reginster J-Y, Sawicki A, Devogelaer JP, et al (2004) Stontium ranelate reduces the risk of hip fracture in women with postmenopausal osteoporosis. Oral presentation, 26th Annual Meeting of the ASBMR. Seattle, Abstract 855

    Google Scholar 

  • Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ (1995) Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med 98(4): 331–335

    Article  PubMed  CAS  Google Scholar 

  • Riggs BL, Hodgson SF, O’Fallon WM, Chao EY, Wahner HW, Muhs JM, Cedel SL, Melton LJ III (1990) Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322: 802–809

    PubMed  CAS  Google Scholar 

  • Riggs BL, O’Fallon WM, Lane A, Hodgson SF, Wahner HW, Muhs J, Chao E, Melton LJ III (1994) Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis. J Bone Miner Res 9(2): 265–275

    Article  PubMed  CAS  Google Scholar 

  • Rodriguez-Martinez MA, Garcia-Cohen EC (2002) Role of Calcium and vitamin D in the prevention and treatment of osteoporosis. Pharmacol Ther 93: 37–49

    Article  PubMed  CAS  Google Scholar 

  • Rosen LS, Gorden D, Kamisnki M, et al (2001) Zoledronat acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7: 377–387

    PubMed  CAS  Google Scholar 

  • Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288: 321–333

    Article  PubMed  CAS  Google Scholar 

  • Rovetta G, Monteforte P, Balestra V (2000) Intravenous clodronate for acute pain induced by osteoporotic vertebral fracture. Drugs Exp Clin Res 26(1): 25–30

    PubMed  CAS  Google Scholar 

  • Rubin MR, Cosman F, Lindsay R, Bilezikian JP (2002) The anabolic effects of parathyroid hormone. Osteoporos Int 13: 267–277

    Article  PubMed  CAS  Google Scholar 

  • Russel RG, Rogers MJ (1999) Bisphosphonates: from the laboratory to the clinic and back again. Bone 25(1): 97–106

    Article  Google Scholar 

  • Schmidt IU, Dobnig H, Turner RT (1995) Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats. Endocrinology 136: 5127–5134

    Article  PubMed  CAS  Google Scholar 

  • Schnitzer T, Bone HG, Cepaldi G (2000) Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging 12: 1–12

    PubMed  CAS  Google Scholar 

  • Simonet, et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309–319

    Article  PubMed  CAS  Google Scholar 

  • Sorensen O, Goemare S, Wenderoth D, Chines A, Roux C (2003) Sustained effect of risedronate: a 7-year study in postmenopausal women. Calcif Tissue Int 72: 402, P-275

    Google Scholar 

  • The North American Menopause Society (2001) The role of calcium in peri and postmenopausal women. Consensus opinion of the North American Menopause Society 8: 84–95

    Google Scholar 

  • Valtola A, Honkanen R, Kroger H, Tuppurainen M, Saarikoski S, Alhava E (2002) Lifestyle and other factors predict ankle fractures in perimenopausal women: a population-based prospective cohort study. Bone 30(1): 238–242

    Article  PubMed  CAS  Google Scholar 

  • Wasnich RD, Miller PD (2000) Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85: 231–236

    Article  PubMed  CAS  Google Scholar 

  • Yoshimura M (2000) Analgesic mechanism of calcitonin. J Bone Miner Metab 18(4): 230–233

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ludwig Boltzmann Institut für Altersforschung, II. Medizinische Abteilung, KH Barmherzige Schwestern, Stumpergasse 13, 1060, Wien, Austria

    Univ.-Prof. Dr. Heinrich Resch & Dr. Christian Muschitz

Authors
  1. Univ.-Prof. Dr. Heinrich Resch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. Christian Muschitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Wirbelsäulenzentrum, 3. Orthopädische Abteilung, Orthopädisches Spital Speising, Vienna, Austria

    Stephan Becker  & Michael Ogon  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag/Wien

About this chapter

Cite this chapter

Resch, H., Muschitz, C. (2008). Drug therapy of osteoporosis. In: Becker, S., Ogon, M. (eds) Balloon Kyphoplasty. Springer, Vienna. https://doi.org/10.1007/978-3-211-74221-1_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-211-74221-1_2

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-74220-4

  • Online ISBN: 978-3-211-74221-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation